Related Experiment Video
Updated: Sep 20, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer
E Bournakis1, A Bournakis1, D V Zolota1,2
1Oncologic Clinical Trials and Research Clinic, Metropolitan General Hospital, Athens, Greece.
Background:
Prostate cancer is a leading cause of cancer death among men. Metastatic castration-resistant prostate cancer (mCRPC) treatment has changed dramatically since the introduction of novel hormonal agents (NHAs); however, real-world data including healthcare resource utilization (HCRU) and costs are lacking in Greece.
Methods:
A subset of patients with HCRU data from the PROSPECT retrospective chart review study of patients with mCRPC who initiated first line (1 L) systemic therapy with chemotherapy or NHAs were included; HCRU and costs incurred during mCRPC treatment were estimated.
Results:
HCRU remained mostly stable across lines for the 119 patients included. Overall, median HCRU cost was €2,363.8 per patient per month (PPPM); 1 L was €2,475.0, second line (2 L) was €1,698.9, third line (3 L) was €2,499.0. Cost was mostly made up of systemic treatment (~90%). Overall HCRU 2 L costs were €688,795.1, contributing the least to the total HCRU cost of the three lines studied (€3,820,561.1). 2 L cost was lower as a greater proportion of patients received chemotherapy than in 1 L or 3 L, and chemotherapy was cheaper than NHAs.
Conclusions:
Cost was impacted by type of systemic treatment; 2 L treatment costs were lower as a higher proportion of patients were treated with chemotherapy rather than NHAs.
